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SUMMARY
We present two clinical cases of lymphadenopathy 
after vaccination with the human papillomavirus (HPV) 
9- valent vaccine: an asymptomatic 11- year- old boy with 
inferior cervical and supraclavicular lymphadenopathy, 
and a 13- year- old girl who presented with 
lymphadenopathy. In both cases, medical history was 
unremarkable and there was no recent infection, or other 
clinical findings. Both adolescents had received the HPV 
9- valent vaccine in the previous week. In the first case, 
blood tests, ultrasonography and biopsy were performed, 
while in the second, a watchful waiting strategy was 
adopted. In both cases, the lymphadenopathy resolved 
spontaneously. The boy received the second dose of 
the vaccine 6 months later and lymphadenopathy 
reappeared. The Naranjo scale was applied, classifying 
the events as definite (in the case of the boy) and 
probable (girl) adverse drug reactions. The vaccine is safe, 
but recognising this minor adverse event is important to 
prevent unnecessary investigation and reduce patient 
and parental anxiety.
BACkgRoUnd
Due to the risk of cervical cancer caused by human 
papillomavirus (HPV), the European Medicines 
Agency (EMA) approved the bivalent (HPV16/18) 
and the quadrivalent (HPV6/11/16/18) HPV 
vaccines in 2006 and 2007, respectively. In 2015, 
the EMA approved the 9- valent HPV vaccine 
(HPV6/11/16/18/31/33/45/52/58), which is 
currently indicated for active immunisation of 
individuals from the age of 9 years against HPV- 
associated diseases.1 HPV vaccination has proved to 
be effective and safe, without major adverse reac-
tions, and has been adopted into national immu-
nisation programmes of most European Union 
countries.2
While most industrialised countries have intro-
duced routine female HPV vaccination into their 
national immunisation programmes, routine 
vaccination of male children/adolescents and men 
is currently only implemented in few countries 
(including Australia, Canada, the USA and Austria). 
Vaccination of males may further reduce the inci-
dence of cervical cancer and precancerous lesions 
via herd protection and reduce the incidence of 
anal, penile, head and neck cancers.3 4
The WHO, Food and Drug Administration, 
Advisory Committee on Immunization Practices, 
National Advisory Committee on Immunization, 
Australian Technical Advisory Group on Immuni-
sation, National Health Service (NHS), Portugal 
Directorate- General of Health (DGS) and other 
regulatory agencies continue to recommend HPV 
vaccination because it is effective, cost- effective and 
safe.5–11
The most common adverse reactions observed 
with the 9- valent HPV vaccine are injection- site 
adverse reactions (pain, swelling and erythema) 
and headache. Other commonly reported adverse 
reactions are dizziness, nausea, fever, fatigue and 
pruritus or bruising at the injection site. In the 
postmarketing experience section of the summary 
of product characteristics, there are some very rare 
events reported voluntarily as injection- site cellu-
litis, immune thrombocytopenic purpura, anaphy-
lactic reactions, bronchospasm, urticaria, acute 
disseminated encephalomyelitis, Guillain- Barré 
syndrome, syncope, vomiting, arthralgia, myalgia, 
asthenia, chills and malaise.1
We reviewed the current literature and found a 
single case report of lymphadenopathy after HPV 
vaccination, described in a 26- year- old woman. 
We did not find any reports of post- HPV 9- valent 
vaccination lymphadenopathy in children.12
CASe pReSenTATion
Case 1
An asymptomatic healthy 11- year- old boy 
presented to a routine paediatric appointment 
4 days after he had received his first dose of the 
HPV 9- valent vaccine in the right deltoid muscle. 
There was no history of fever, weakness, fatigue, 
night sweats, recent diseases or travels, nor close 
contact with cats or other animals. Apart from 
pectus excavatum, he had no relevant personal 
or family medical history. Physical examination 
revealed a non- tender right- sided inferior cervical 
and supraclavicular lymph node, rubbery and 
mobile, without erythema or other inflammatory 
signs. The largest diameter was approximately 
1 cm. There was no other palpable lymphadenop-
athy elsewhere, and no splenomegaly. There were 
no signs of inflammation in the right deltoid region. 
The rest of his physical examination was unre-
markable. Ten days after the first appointment, he 
was reassessed, and the abnormal lymph node had 
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Figure 1 Palpable non- tender left- sided inferior cervical lymph node 
with a diameter of approximately 1.5 cm.
Figure 2 The first ultrasound of the 13- year- old boy showing three 
nodular structures, the largest with a bigger axis of 14.8 mm, both well- 
delineated.
Figure 3 Increased Doppler signal, in the largest nodular structure, 
suggesting a recently developing adenopathy.
Case 2
A 13- year- old girl presented to paediatric emergency department 
complaining of a swelling in the neck 5 days after receiving the 
first dose of the HPV 9- valent vaccine. The patient’s personal 
medical background and family medical history were both unre-
markable. She was otherwise asymptomatic and, apart from a 
palpable non- tender left- sided inferior cervical lymph node 




After the first appointment, the 11- year- old boy underwent 
blood tests that were unremarkable (haemoglobin 137 g/L, leuco-
cytes 7.7×109/L—4.10×109/L neutrophils and 3.04×109/L 
lymphocytes, platelets 284×109/L, erythrocyte sedimentation 
rate 3 mm/hour, c reactive protein 0.09 mg/dL, lactate dehy-
drogenase 249 U/L, aspartate transaminase 23 U/L and alanine 
transaminase 22 U/L). A peripheral blood smear was normal. 
An ultrasound was performed that revealed four nodular struc-
tures, the largest with a long axis of 15 mm (the remaining struc-
tures measured 9, 8 and 7.2 mm), all well- delineated and with 
increased Doppler signal, findings suggestive of recent devel-
oping adenopathies (figures 2 and 3). When the patient was 
reassessed 10 days after the first appointment, blood tests were 
repeated, and the results were unremarkable. Epstein- Barr virus, 
Toxoplasma gondii, cytomegalovirus and Bartonella henselae 
serologies were all negative. Thirteen days after the first ultra-
sound, the patient repeated sonographic evaluation showing 
the same four ganglionic structures with the following dimen-
sions: 14×6.8, 9.3×4.4, 8.6×4.6 and 5.7×2.7 mm (figure 4). 
All lymph nodes were rounded, strongly hypoechogenic, with 
little Doppler signal, not suggestive of reactive changes. Chest 
X- ray was normal. The patient underwent a biopsy of the largest 
two lymph nodes, which showed exuberant follicular lymphoid 
hyperplasia and hyperplasia of the parafollicular areas without 
changes of the mantle layer (figure 5). The biopsy showed non- 
specific reactive hyperplasia with no granulomas and no features 
of lymphoma.
Case 2
A watchful waiting strategy was adopted, and no investigations 
were performed.
diFFeRenTiAl diAgnoSiS
In a paediatric population, lymphadenopathy is a very common 
finding and usually provoked by a reaction to viral antigens; 
therefore, the most common cause is viral infection; however, 
a postvaccination aetiology should be considered. Lymphade-
nopathy can also be caused by bacteria (acute bacterial lymph-
adenitis), fungi and parasites. Less frequently, there are other 
non- infectious causes, such as malignancies, metastasis and some 
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Figure 4 The second ultrasound of the 13- year- old boy 13 days after 
the first. The largest adenopathy is represented with similar dimensions 
but with a weaker Doppler signal.
Figure 5 Exuberant follicular lymphoid hyperplasia in the lymph node cortical region, and no changes in the mantle layer. H&E staining, 
magnification ×4 and ×10.
location is a rarer and more worrisome finding suggesting either 
primary lymphatic malignancy, infection in the mediastinum or 
a metastatic malignancy from the abdomen.14
In both cases, patients had no history of a viral prodrome, and 
the lymph nodes were not tender to palpation, which helps to 
exclude lymphadenopathy secondary to viral infection. In the 
absence of fever, tenderness on palpation and overlying erythema 
acute bacterial lymphadenitis are less likely. There was no history 
or findings that would point towards a malignant diagnosis, such 
as night sweats, fatigue, easy bleeding or bruising, weight loss, or 
firm and indurated masses on physical examination.
TReATMenT
Four weeks after the first presentation, the 11- year- old boy 
underwent an excisional biopsy.
There was no therapeutic intervention in the second case.
oUTCoMe And Follow-Up
One month after the procedure, the 11- year- old boy had no 
palpable lymphadenopathy in the cervical and supraclavic-
ular regions. Six months after the first vaccination, the patient 
received the second dose of the HPV vaccine in the left deltoid 
region and subsequently developed lymphadenopathy in the 
same region with the same clinical findings. He was reassessed 
3 months after the second dose and there were no palpable 
lymphadenopathy. We calculated the Naranjo score and the 
result was 10, suggestive of a ‘definite’ adverse drug reaction 
(ADR).
Two months after the first appointment, the 13- year- old 
girl was asymptomatic with no palpable lymphadenopathy on 
examination. She has not yet received a second dose of the HPV 
vaccine. The Naranjo score was 7, a ‘probable’ ADR.
diSCUSSion
Confronted with these two cases of acute lymphadenopathy, 
we considered the most common aetiologies as possible causes. 
Once again, the most useful diagnostic tool was the history 
and physical examination. If the clinical diagnosis is question-
able, imaging may be required. Ultrasonography can be used to 
further delineate the nature of the lymph node. Patients who 
continue to have persistent symptoms for more than 4–6 weeks 
despite appropriate therapies may require an excisional biopsy.13
In both cases, there was no history of a viral prodrome or 
active disease and no signs of local infection. In the first case, 
we decided to perform blood analysis, including serologies, 
ultrasounds and biopsies. This strategy was adopted due to the 
persistence of the supraclavicular lymphadenopathy 4 weeks 
after the initial presentation, despite the absence of other medical 
history, presenting complaints or examination findings sugges-
tive of a malignancy aetiology. In the case of the 13- year- old 
girl, who had no medical history, current disease or worrying 
findings on clinical examination, we were able to adopt a more 
conservative approach. Our attitude in the second case was also 
probably influenced after a literature review found the previous 
case reported in this article.
After ruling out the most common and potentially serious 
aetiologies, we hypothesised that this could be a postvaccine 
reaction. As stated previously, the summary of product charac-
teristics for the vaccine did not include lymphadenopathy as one 
of the possible adverse reactions.1 The safety of HPV vaccination 
has been evaluated carefully in several countries that have imple-
mented it in national immunisation programmes. In Denmark 
and Sweden, there was no evidence of increased risk of autoim-
mune events, neurological events or venous thromboembolism.15 
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learning points
 ► Paediatricians should be aware that lymphadenopathy may 
occur after human papillomavirus (HPV) vaccination to 
prevent unnecessary patient concern and procedures, such as 
blood analyses, ultrasound or lymph node biopsies.
 ► The HPV vaccine has proved to be effective and safe and the 
knowledge of this minor adverse event should not prevent 
paediatricians from recommending this vaccination to the 
adolescent population.
 ► The HPV vaccine is recent, so postmarketing surveillance 
must be maintained to detect any possible adverse events 
following HPV immunisation.
(AEFI) were reported at a rate of 1.9/10 000 doses. Primarily, 
the AEFI were allergic reaction (25%), rash (22%) and injection- 
site reaction (20%), while 26% of reports had a non- specific 
event. In the UK, the NHS classifies HPV vaccine side effects as 
very common (redness, swelling or pain at the site of the injec-
tion, and headaches), common (bruising or itching at the site 
of the injection, a high temperature or feeling hot and shivery, 
and nausea and pain in the arms, hands, fingers, legs, feet or 
toes), rare (an itchy red rash), very rare (difficulty breathing and 
restriction of the airways) and others (bruising or bleeding more 
easily, chills, weakness, tiredness or general feeling unwell, pain 
or tenderness in the joints or muscles, vomiting and seizures).16
Despite not having found any report of post- HPV vaccination 
lymphadenopathy in children, we decided to apply the Naranjo 
Adverse Drug Reaction Probability Scale, which is a simple 
method developed to assess the causality of ADRs in a variety of 
clinical situations and proved to offer a sensitive way to monitor 
ADRs and to be able to be applicable to postmarketing drug 
surveillance. It classifies the ADRs as definite, possible, probable 
or doubtful.17
By applying this score to the 11- year- old boy case, we reach a 
total score of 10, corresponding to the classification of a definite 
ADR which means the reaction followed a reasonable temporal 
sequence after a drug or in which a toxic drug level had been 
established in body fluids or tissues, followed a recognised 
response to the suspected drug, and was confirmed by improve-
ment after stopping the drug and reappearance on re- exposure.
When applying the same scale to the 13- year- old girl, we 
obtained a lower score (7), representing a probable ADR. The 
patient had not yet received the second dose of the vaccine, so 
we could not confirm reappearance after the re- administration 
of the drug.
Despite the AEFI’s noticed in these two case reports, only 
previously described once, we do not think our findings should 
prevent the routine HPV vaccination. In both cases, the adverse 
events were non- serious conditions whose only impact was the 
over the investigation of the first case, which we hope to help 
prevent by making paediatricians aware that lymphadenopathy 
may follow HPV vaccination.
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